UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022194
Receipt number R000025568
Scientific Title Invasive intervention study on the safety of fibrinogen concentrate used in obstetric hemorrhage
Date of disclosure of the study information 2016/05/09
Last modified on 2020/11/04 16:54:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Invasive intervention study on the safety of fibrinogen concentrate used in obstetric hemorrhage

Acronym

Invasive intervention study on the safety of fibrinogen concentrate used in obstetric hemorrhage

Scientific Title

Invasive intervention study on the safety of fibrinogen concentrate used in obstetric hemorrhage

Scientific Title:Acronym

Invasive intervention study on the safety of fibrinogen concentrate used in obstetric hemorrhage

Region

Japan


Condition

Condition

obstetric hemorrhage

Classification by specialty

Obstetrics and Gynecology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Clarify the frequency of occurrence of side effects during use of fibrinogen concentrate for hypofibrinogenemia at the time of obstetric hemorrhage.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The incidence of transfusion-associated circulatory overload(TACO) due to the large amount of blood transfusion for less than one week after the intervention start

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Self control

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

We will be administered in single dose of fibrinogen concentrate 3g

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

1) patient during pregnancy or postpartum
2) patient who meet any of the following 1-4
1.SI value> 1.0 or vaginal delivery when the amount of bleeding> 1000ml (cesarean section when the amount of bleeding> 2000ml), patients which is more persistent bleeding is found
2.SI value> 1.5 are observed frequently.
3.obstetric DIC score more than 8 points
4.objective symptoms suggestive of circulatory failure
such as oliguria, peripheral cold sweat and SpO2 decrease.
3)inpatient and outpatient
4)Patient consent with respect to participation in this study has been obtained in writing

Key exclusion criteria

Patient who are judged to be inappropriate as a target by the discretion of physician.

Target sample size

25


Research contact person

Name of lead principal investigator

1st name Akira
Middle name
Last name Iwase

Organization

Gunma University Hospital

Division name

Obstetric & Gynecology

Zip code

3718511

Address

3-39-15, Showa-machi, maebashi-shi, gunma

TEL

027-220-8436

Email

daisukeh@gunma-u.ac.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Higeta

Organization

Gunma University Hospital

Division name

Obstetric & Gynecology

Zip code

3718511

Address

3-39-15, Showa-machi, maebashi-shi, gunma

TEL

027-220-8436

Homepage URL


Email

daisukeh@gunma-u.ac.jp


Sponsor or person

Institute

Gunma University

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Gunma University Hospital Clinical Research Review Board

Address

3-39-15, Showa-machi, maebashi-shi, gunma

Tel

027-220-8740

Email

daisukeh@gunma-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 05 Month 09 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2016 Year 04 Month 27 Day

Date of IRB

2016 Year 04 Month 28 Day

Anticipated trial start date

2016 Year 05 Month 01 Day

Last follow-up date

2022 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 05 Month 02 Day

Last modified on

2020 Year 11 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025568


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name